Antitumor activity of interleukin 12 in preclinical models
Michael J. Brunda(La Roche College), Alicia V. Palleroni(Roche (Switzerland)), Leopoldo Luistro(Johnson & Johnson (United States)), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Rosemary Wright(Roche (Switzerland)), Anthony Aglione(Roche (Switzerland)), Leonid Rumennik(Roche (Switzerland)), Robert H. Wiltrout(Frederick National Laboratory for Cancer Research), Jill A. Hendrzak(Roche (Switzerland)), Mark Dvorozniak(Roche (Switzerland))
Cited by 94
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k